i-PDTA Pilot Clinical Trial to Reduce Side-Effects of Photodynamic Therapy for the Treatment of Moderate to Severe Acne
20 % Aminolevulinic Acid
+ 20 % Aminolevulinic Acid
+ Blue light only
Manifestaciones Neurológicas+4
+ Enfermedades de las Glándulas Sebáceas
+ Signos y Síntomas
Estudio de Tratamiento
Resumen
Fecha de inicio: 1 de noviembre de 2009
Fecha en la que se inscribió al primer participante.This is a pilot study to compare efficacy and side effects i-PDT and ALA-PDT. All subjects will receive ALA-PDT and i-PDT. Face or back regions will be divided into two sides, the right and left. One half of the face or back will receive ALA-PDT and the other half will receive i-PDT. For subjects with back acne, red light and blue light alone will be applied for comparison. Healthy subjects with difficult to treat moderate or severe acne on the face or back are eligible to enroll. The investigators will enroll about 35 patients at Massachusetts General Hospital (MGH) with follow-ups 1, 3 and 6 months after treatment.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 35 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Tratamiento
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.De 14 a 50 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Inclusion criteria Subjects with ages between 14 and 50 years, male or female. Subjects with severe acne lesions (one or more nodules or cysts present) on their backs or face Presence of moderate acne on the back and/or face that has been recalcitrant to previous treatments. Recalcitrant acne is acne with no or mild/temporary (less than 3 months) improvement after using: Accutane® for at least one completed treatment cycle, and/or Oral antibiotic for ≥ 3 months; and/or Topical prescription retinoids (tretinoin - retinoic acid, adapalene, tazarotene or other derivatives) for ≥ 3 months, and/or Topical benzoyl peroxide 2.5% or higher concentrations for ≥ 3 months Hormonal treatments** for ≥ 3 months. Willingness to participate in the study Willingness to receive ALA-PDT treatment Informed consent agreement signed by the subject Willingness to follow the treatment schedule and post treatment care requirements Willingness to not use topical or systemic (oral) anti-acne medications including medicated shampoo or soap during the study period. Exclusion criteria Subjects receiving concurrent oral retinoids or antibiotics ** Subjects with chronic use of antibiotics may be included if proven that its use has not changed the severity of their acne. AND *** Chronic use of antibiotic is considered ≥ 2 years of continuous use. Scarring or infection of the area to be treated Known photosensitivity Presence of suntan in the area to be treated Subjects who have taken medication known to induce photosensitivity in the previous 3 months Subjects who have had prior oral retinoid (Accutane®) use within 6 months of entering the study Prior oral antibiotic use within 1 month of entering the study (see exclusion #1) Topical antibiotic or other topical anti-acne treatments use within 2 weeks of entering the study Known anticoagulation or thromboembolic condition Subjects who are immunosuppressed Subject is unable to comply with treatment, home care or follow-up visits Subject is pregnant or breast feeding Subject has a history of being on photosensitive medications (thiazides [used to treat high blood pressure], tetracyclines, fluoroquinolones griseofulvin or sulfonamides [used to treat infections], sulfonylureas [used to treat diabetes], calcium channel blockers [used to treat hypertension]. phenothiazines [used to treat serious emotional problems]). Known skin sensitivity to blue light Porphyria (a disorder of the metabolism that can lead to sensitivity to light) Allergies to chemicals called porphyrins Subjects who started hormonal treatment (for medical conditions or birth control) within less than 3 months.
Plan de Estudio
Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.5 grupos de intervención están designados en este estudio
0% de probabilidad de ser asignado al grupo placebo
Grupos de Tratamiento
Grupo I
Sin IntervenciónGrupo II
Comparador ActivoGrupo III
ExperimentalGrupo IV
Comparador ActivoGrupo 5
Comparador ActivoObjetivos del Estudio
Objetivos Primarios
Objetivos Secundarios